Urology Today.net

Site updated at Thursday, 12 May 2016

Common Urological Problems


FDA Approves Xtandi for Late-Stage Castration-Resistant Prostate Cancer

The U.S. Food and Drug Administration today approved Xtandi (enzalutamide) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.

Approved for prostate cancer patients previously treated with docetaxel, another anti-cancer treatment, Xtandi was reviewed under the FDA’s priority review program.… FDA Approves Xtandi for Late-Stage Castration-Resistant Prostate Cancer   

avodart1 - phosphate stones2 - urinary-tract infections1 - preemptive kidney transplantation1 - reiter's syndrome2 - fish1 - nephron-sparing surgery1 - ultrasonic imaging1 - hypertensive nephropathy1 - kidney disorder1 - cardiovascular mortality1 - johnson & johnson1 - dana-farber cancer institute1 - mild kidney disease1 - pregnancy7 - rectocele5 - dietary fat1 - gene1 - kidney health3 - altered appetite1 - aggressive prostate cancer9 - proteins ralb1 - uric acid nephropathy1 - alport disease1 - xanthogranulomatous pyelonephritis1 - xenical1 - advanced renal disease1 - biopsy for prostate cancer1 - anti-inflammatory drugs1 - jama1 -